Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 48.53
+0.25 (0.52%)
Jul 29, 2026, 4:00 PM EDT
SHE:301075 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 134.66 | 151.67 | 239.92 | 333.67 | 400.98 | 529.62 |
Other Revenue | 2.51 | 2.51 | 0.71 | 0.63 | 0.07 | - |
| 137.16 | 154.18 | 240.63 | 334.3 | 401.05 | 529.62 | |
Revenue Growth | -43.00% | -35.93% | -28.02% | -16.64% | -24.27% | 8.05% |
Cost of Revenue | 136.21 | 147.4 | 148.82 | 106.19 | 92.68 | 60.43 |
Gross Profit | 0.96 | 6.78 | 91.8 | 228.11 | 308.37 | 469.19 |
Selling, General & Admin | 72.77 | 79.99 | 135.04 | 202.13 | 272.76 | 374.79 |
Research & Development | 31.52 | 32.41 | 37 | 24 | 26.45 | 24.07 |
Other Operating Expenses | 2.86 | 2.72 | 1.93 | 3.71 | 4.64 | 6.59 |
Operating Expenses | 112.89 | 123.68 | 179.62 | 230.68 | 306.56 | 406.8 |
Operating Income | -111.94 | -116.9 | -87.81 | -2.57 | 1.81 | 62.38 |
Interest Expense | -17.07 | -17.94 | -7.9 | -3.11 | -1.36 | -1.18 |
Interest & Investment Income | 0.76 | 2.08 | 10.07 | 13.36 | 9.3 | 1.16 |
Currency Exchange Gain (Loss) | -0 | -0 | - | - | - | - |
Other Non Operating Income (Expenses) | -3.29 | -3.38 | -1.74 | 1.71 | -0.2 | -0.07 |
EBT Excluding Unusual Items | -131.54 | -136.14 | -87.39 | 9.39 | 9.55 | 62.3 |
Impairment of Goodwill | -0.17 | -0.17 | -0.23 | -0 | - | - |
Gain (Loss) on Sale of Investments | -0.17 | 0.04 | 0.54 | 0.07 | - | -0.2 |
Gain (Loss) on Sale of Assets | -0.17 | -0.11 | 0.04 | 0.08 | - | - |
Asset Writedown | -1.16 | -0.83 | -0.05 | -0.01 | -0.01 | -0 |
Other Unusual Items | 5.74 | 5.85 | 1.31 | 12.72 | 11.48 | 11.18 |
Pretax Income | -127.46 | -131.36 | -85.77 | 22.25 | 21.02 | 73.28 |
Income Tax Expense | 1.24 | 1.04 | -0.75 | 5.16 | 2.44 | 7.42 |
Earnings From Continuing Operations | -128.7 | -132.4 | -85.03 | 17.09 | 18.58 | 65.86 |
Minority Interest in Earnings | 28.16 | 30.23 | 22.36 | 1.76 | 1.92 | 2.65 |
Net Income | -100.54 | -102.17 | -62.67 | 18.85 | 20.5 | 68.51 |
Net Income to Common | -100.54 | -102.17 | -62.67 | 18.85 | 20.5 | 68.51 |
Net Income Growth | - | - | - | -8.05% | -70.07% | -25.53% |
Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 79 | 65 |
Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 79 | 65 |
Shares Change | -0.28% | -0.16% | 0.99% | -0.39% | 20.86% | 8.52% |
EPS (Basic) | -1.27 | -1.29 | -0.79 | 0.24 | 0.26 | 1.05 |
EPS (Diluted) | -1.27 | -1.29 | -0.79 | 0.24 | 0.26 | 1.05 |
EPS Growth | - | - | - | -7.69% | -75.24% | -31.37% |
Free Cash Flow | -188.54 | -147.65 | -108.09 | -11.28 | -31.6 | 42.8 |
Free Cash Flow Per Share | -2.38 | -1.86 | -1.36 | -0.14 | -0.40 | 0.66 |
Dividend Per Share | - | - | - | 0.125 | - | 0.625 |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 0.70% | 4.40% | 38.15% | 68.24% | 76.89% | 88.59% |
Operating Margin | -81.61% | -75.82% | -36.49% | -0.77% | 0.45% | 11.78% |
Profit Margin | -73.30% | -66.27% | -26.04% | 5.64% | 5.11% | 12.93% |
Free Cash Flow Margin | -137.46% | -95.77% | -44.92% | -3.37% | -7.88% | 8.08% |
EBITDA | -57.63 | -68.07 | -60.86 | 15.76 | 16.44 | 76.07 |
EBITDA Margin | -42.01% | -44.15% | -25.29% | 4.71% | 4.10% | 14.36% |
D&A For EBITDA | 54.31 | 48.84 | 26.95 | 18.33 | 14.63 | 13.68 |
EBIT | -111.94 | -116.9 | -87.81 | -2.57 | 1.81 | 62.38 |
EBIT Margin | -81.61% | -75.82% | -36.49% | -0.77% | 0.45% | 11.78% |
Effective Tax Rate | - | - | - | 23.18% | 11.61% | 10.12% |
Revenue as Reported | 137.16 | 154.18 | 240.63 | 334.3 | 401.05 | 529.62 |
Advertising Expenses | - | 10.16 | 62.61 | 145.61 | 217.83 | 315.11 |